Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

Minoryx Therapeutics receives Orphan Drug…

Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS

Notice of Business Alliance between…

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics receives FDA Orphan…

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

Immunic, Inc. Expands Board of…

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Immunic, Inc. Announces Completion of…

Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics completes enrollment in…

Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference

Novadip Biosciences Presents Clinical Case…

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

FierceBiotech names Confo Therapeutics as…

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

Immunic, Inc. Doses First Healthy…

Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

Immunic, Inc.'s Interim Dosing Analysis…